Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

IGKV1-5 antibody

The Rabbit Polyclonal anti-IGKV1-5 antibody has been validated for WB and ELISA. It is suitable to detect IGKV1-5 in samples from Human and Mouse.
Catalog No. ABIN7115198

Quick Overview for IGKV1-5 antibody (ABIN7115198)

Target

IGKV1-5 (Immunoglobulin kappa Variable 1-5 (IGKV1-5))

Reactivity

Human, Mouse

Host

  • 1
  • 1
Rabbit

Clonality

  • 2
Polyclonal

Conjugate

  • 2
This IGKV1-5 antibody is un-conjugated

Application

Western Blotting (WB), ELISA
  • Purpose

    IGKV1-5 antibody

    Purification

    Immunogen affinity purified

    Purity

    ≥95 % as determined by SDS-PAGE

    Immunogen

    immunoglobulin kappa variable 1-5

    Isotype

    IgG
  • Application Notes

    WB: 1:500-1:2000

    Restrictions

    For Research Use only
  • Format

    Liquid

    Buffer

    PBS with 0.02 % sodium azide and 50 % glycerol pH 7.3,

    Preservative

    Sodium azide

    Precaution of Use

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Handling Advice

    Avoid repeated freeze / thaw cycles.

    Storage

    -20 °C

    Storage Comment

    -20°C for 12 months

    Expiry Date

    12 months
  • Target

    IGKV1-5 (Immunoglobulin kappa Variable 1-5 (IGKV1-5))

    Alternative Name

    IGKV1-5

    Background

    Synonyms: Immunoglobulin kappa variable 1-5|Ig kappa chain V-I region CAR|Ig kappa chain V-I region EU|Ig kappa chain V-I region HK102|Ig kappa chain V-I region Kue|IGKV1-5

    Background: V segment of the variable domain of immunoglobulins light chain that participates to the antigen recognition. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens(PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen(PubMed:20176268, PubMed:17576170).

    UniProt

    P01602
You are here:
Chat with us!